As of June 30, 2025, cash, cash equivalents and marketable securities totaled $166.2 million compared to cash, cash equivalents and marketable securities of $197.9 million as of March 31, 2025. The decrease in cash is related to funding ongoing operations. Cash is expected to support current clinical and operational activities into early 2027.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABOS:
- ABOS Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Acumen Pharmaceuticals’ Promising Alzheimer’s Study: A Potential Game-Changer?
- Acumen presents results from its Phase 2 ALTITUDE-AD study of sabirnetug
- Strategic Buy Rating for Acumen Pharmaceuticals: Leveraging JCR Collaboration to Enhance Asset Delivery and Differentiation
- Acumen Pharmaceuticals Partners with JCR for Alzheimer’s Treatment